STOCK TITAN

Jaguar Health to Host Investor Webcast Monday, March 14th at 8:30 AM Eastern Time Regarding Q4 2021 Financials & Corporate Updates

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Jaguar Health (NASDAQ:JAGX) has announced an investor webcast scheduled for March 14, 2022, at 8:30 AM ET to discuss its Q4 2021 financials and corporate updates. The company plans to file its Annual Report on March 11, 2022, for the fiscal year ending December 31, 2021. Jaguar focuses on developing plant-based, non-opioid prescription medicines for gastrointestinal distress. Their crofelemer drug candidate is being evaluated in a pivotal Phase 3 clinical trial. For more information, visit jaguar.health.

Positive
  • None.
Negative
  • None.

Click here to register for webcast

Company plans to file its Annual Report on March 11, 2022 on Form 10-K for the fiscal year ended December 31, 2021

SAN FRANCISCO, CA / ACCESSWIRE / March 7, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that company management will host an investor webcast on Monday, March 14, 2022, at 8:30 a.m. Eastern Time to review fourth-quarter 2021 financials and provide corporate updates.

Participation Instructions for Webcast

When: Monday, March 14, 2022, at 8:30 AM Eastern Time

Participant Registration & Access Link: Click Here

About Jaguar Health, Jaguar Animal Health, Napo Pharmaceuticals & Napo Therapeutics

Jaguar Health is a commercial stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, including chronic, debilitating diarrhea. Jaguar Animal Health is a tradename of Jaguar Health. Jaguar Health's wholly owned subsidiary, Napo Pharmaceuticals, focuses on developing and commercializing proprietary plant-based human pharmaceuticals from plants harvested responsibly from rainforest areas. Our crofelemer drug product candidate is the subject of the OnTarget study, an ongoing pivotal Phase 3 clinical trial for prophylaxis of diarrhea in adult cancer patients receiving targeted therapy. Jaguar Health is the majority shareholder of Napo Therapeutics, an Italian corporation established by Jaguar Health in Milan, Italy in 2021 that focuses on expanding crofelemer access in Europe.

For more information about Jaguar Health, please visit https://jaguar.health. For more information about Napo Pharmaceuticals, visit www.napopharma.com. For more information about Napo Therapeutics, visit www.napotherapeutics.com.

Forward-Looking Statements

Certain statements in this press release constitute "forward-looking statements." These include statements regarding Jaguar Health's expectation that an investor webcast will take place March 14, 2022. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Contact:

Peter Hodge
Jaguar Health, Inc.
phodge@jaguar.health
Jaguar-JAGX

SOURCE: Jaguar Health, Inc.



View source version on accesswire.com:
https://www.accesswire.com/691592/Jaguar-Health-to-Host-Investor-Webcast-Monday-March-14th-at-830-AM-Eastern-Time-Regarding-Q4-2021-Financials-Corporate-Updates

FAQ

When is Jaguar Health's investor webcast?

Jaguar Health's investor webcast is scheduled for March 14, 2022, at 8:30 AM Eastern Time.

What financial results will Jaguar Health discuss in the webcast?

Jaguar Health will discuss its Q4 2021 financial results during the webcast.

When will Jaguar Health file its Annual Report?

Jaguar Health plans to file its Annual Report on March 11, 2022.

What is the focus of Jaguar Health's business?

Jaguar Health focuses on developing plant-based, non-opioid prescription medicines for gastrointestinal issues.

What is the status of Jaguar Health's crofelemer drug candidate?

The crofelemer drug candidate is currently undergoing a pivotal Phase 3 clinical trial.

Jaguar Health, Inc.

NASDAQ:JAGX

JAGX Rankings

JAGX Latest News

JAGX Stock Data

10.44M
9.24M
11.64%
1.14%
7.31%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
SAN FRANCISCO